This training focuses on assessing clinical data for therapeutic indication, licence, and labeling. Topics include structured benefit–risk assessment, consistency with EMA/FDA frameworks, evaluating indicated populations, and judging the generalizability of trial results (including multiregional studies and pharmacogenomics) to support clear, defensible label decisions.
Lecturers: Elimika Pfuma Fletcher, Professor Stuart Walker